<DOC>
	<DOC>NCT01305746</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.</brief_summary>
	<brief_title>A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Completed the treatment period specified in study ANSLE3321 or were enrolled in study ANSLE3321 prior to November 30, 2010 Developed a new medical disease or condition that has made the subject unsuitable for this study in the opinion of the Investigator, including interference with written informed consent, study evaluation, completion, and/or procedures Pregnant or nursing Any prior administration of a Bcell modulating therapy other than A623 Received cyclophosphamide, cyclosporine, antiTNF alpha therapies, transfusion, plasmapheresis or plasma exchange, IV immunoglobulin, or live vaccines according to listed washout periods</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Lupus Erythematosus, Systemic</keyword>
	<keyword>A-623</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Blisibimod</keyword>
</DOC>